Chemotherapy in metastatic colorectal cancer

Surgical Oncology

Volumn 16, Issue 1, 2007, Pages 65-70

  Kelly, Claire ^a   Cassidy, Jim ^a  

^a BEATSON WEST OF SCOTLAND CANCER CENTRE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

BEVACIZUMAB; CAPECITABINE; CETUXIMAB; DNA TOPOISOMERASE; FLUOROPYRIMIDINE DERIVATIVE; FLUOROURACIL; FOLINIC ACID; IRINOTECAN; OXALIPLATIN; TEGAFUR; VASCULOTROPIN;

ACNE; AGING; CANCER CHEMOTHERAPY; CANCER STAGING; CANCER SURVIVAL; CLINICAL TRIAL; COLORECTAL CANCER; CONTINUOUS INFUSION; DIARRHEA; DISEASE COURSE; FATIGUE; FEBRILE NEUTROPENIA; HAND FOOT SYNDROME; HUMAN; HYPERBILIRUBINEMIA; HYPERTENSION; INTESTINE PERFORATION; LIVER METASTASIS; METASTASIS; MONOTHERAPY; MUCOSA INFLAMMATION; NAUSEA; PRIORITY JOURNAL; QUALITY OF LIFE; RASH; REVIEW; STOMATITIS; WOUND HEALING IMPAIRMENT;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; COLORECTAL NEOPLASMS; HUMANS; LIVER NEOPLASMS;

EID: 34249946014     PISSN: 09607404     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.suronc.2007.04.006     Document Type: Review

References (27)

1. CancerStats: Cancer Research UK 2005.
2. Obrand D.I., and Gordon P.H. Incidence and patterns of recurrence following curative resection for colorectal carcinoma. Disease of the Colon and Rectum 40 (1997) 15-24
3. Scheithauer W., Rosen H., Kornek G.V., Sebasta C., and Depisch D. Randomised comparison of combination chemotherapy plus supportive care with supportive care alone in patients with metastatic colorectal cancer. British Medical Journal 306 6880 (1993) 752-755 [Mar20]
4. Hoff P.M., Ansari R., Batist G., Cox J., Kocha W., Kuperminc M., et al. Comparison of oral capecitabine versus intravenous fluorouracil plus leucovorin as first line treatment in 605 patienst with metastatic colorectal cancer: results of a randomised phase III study. Journal of Clinical Oncology 19 8 (2001) 2282-2292 [Apr 15]
5. Van Cutsem E., Twelves C., Cassidy J., Allman D., Bajetta E., Boyer M., et al. Xeloda Colorectal Cancer Study Group. Oral Capecitabine compared with intravenous fluorouracil plus leucovorin in patients with metastatic colorectal cancer: results of a large phase III study. Journal of Clinical Oncology 19 21 (2001) 4097-4106 [Nov1]
6. Cunningham D., Pyrhonen S., James R.D., Punt C.J., Hichish T.F., Heikkila R., et al. Randomised trial of irinotecan plus supportive care versus supportive care alone after fluorouracil failure for patients with metastatic colorectal cancer. Lancet 352 9138 (1998) 1413-1418 [Oct 31]
7. Rougier P., Van Cutsem E., Bajetta E., Niederle N., Possinger K., Labianca R., et al. Randomised trail of irinotecan versus fluorouracil by continuous infusion after fluorouracil failure in patients with metastatic colorectal cancer. Lancet 352 9138 (1998) 1407-1412 [Oct 31]
8. Douillard J.Y., Cunningham D., Roth A.D., Navarro M., James R.D., Karasek P., et al. Irinotecan combined with fluorouracil compared with fluorouracil alone as first line treatment for metastatic colorectal cancer: a multicentre randomised trial. Lancet 355 9209 (2000) 1041-1047 [Mar 25]
9. Saltz L.B., Cox J.V., Blanke C., Rosen L.S., Ferenbacher L., Moore M.J., et al. Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer. Irinotecan Study Group. New England Journal of Medicine 343 13 (2000) 905-914 [Sept 28]
10. Kohne C.H., van Cutsem E., Wils J., Bokemeyer C., El-Serafi M., Lutz M.P., et al. European Organisation for Research and Treatment of Cancer Gastrointestinal Group. Phase III study of weekly high-dose infusional fluorouracil plus folinic acid with or without irinotecan in patients with metastatic colorectal cancer: European Organisation for Research and Treatment of Cancer Gastrointestinal Group Study 40986. Journal of Clinical Oncology 23 22 (2005) 4811-4814 [Aug 1]
11. Ychou M., Douillard J.Y., Rougier P., Adenis A., Mousseau M., Dufour P., et al. Randomized comparison of prophylactic antidiarrheal treatment versus no prophylactic antidiarrheal treatment in patients receiving CPT-11 (irinotecan) for advanced 5-FU-resistant colorectal cancer: an open-label multicenter phase II study. American Journal of Clinical Oncology 23 2 (2000) 143-148 [Apr]
12. Giacchetti S., Perpoint B., Zidani R., Le Bail N., Faggiuolo R., Focan C., et al. Phase III multicenter randomized trial of oxaliplatin added to chronomodulated fluorouracil-leucovorin as first-line treatment of metastatic colorectal cancer. Journal of Clinical Oncology 18 1 (2000) 136-147 [Jan]
13. de Gramont A., Figer A., Seymour M., Homerin M., Hmissi A., Cassidy J., et al. Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer. Journal of Clinical Oncology 18 16 (2000) 2938-2947 [Aug]
14. Grothey A., Deschler B., Kroening H., Ridwelski K., Reichardt P., Kretzschmar A., et al. Phase III study of bolus 5-fluorouracil (5-FU)/folinic acid (FA) (Mayo) vs weekly high-dose 24 h 5-FU infusion/FA+oxaliplatin (OXA) (FUFOX) in advanced colorectal cancer (ACRC). Proceedings of the American Society of Clinical Oncology 22 (2002) 512
15. Giacchetti S., Itzhaki M., Gruia G., Adam R., Zidani R., Kunstlinger F., et al. Long-term survival of patients with unresectable colorectal cancer liver metastases following infusional chemotherapy with 5-fluorouracil, leucovorin, oxaliplatin and surgery. Annals of Oncology 10 6 (1999) 663-669 [Jun]
16. Adam R., Delvart V., Pascal G., Valeanu A., Castaing D., Azoulay D., et al. Rescue surgery for unresectable colorectal liver metastases downstaged by chemotherapy: a model to predict long-term survival. Annals of Surgery 240 4 (2004) 644-657 (October; discussion 657-8.)
17. Goldberg R.M., Sargent D.J., Morton R.F., Fuchs C.S., Ramanathan R.K., Williamson S.K., et al. A randomized controlled trial of fluorouracil plus leucovorin, irinotecan, and oxaliplatin combinations in patients with previously untreated metastatic colorectal cancer. Journal of Clinical Oncology 22 1 (2004) 23-30 (January 1; Epub 2003 December 9)
18. Tournigand C., Andre T., Achille E., Lledo G., Flesh M., Mery-Mignard D., et al. FOLFIRI followed by FOLFOX6 or the reverse sequence in advanced colorectal cancer: a randomized GERCOR study. Journal of Clinical Oncology 22 2 (2004) 229-237 (January 15; Epub 2003 December 2)
19. Cassidy J. First efficacy and safety results from XELOX -1/NO16966, a randomised 2×2 factorial phase III trial of XELOX (X) vs FOLFOX4 (F)+bevacizumab (B) or placebo (P) in first line metastatic colorectal cancer (MCRC) LBA3 31st ESMO Congress 2006.
20. Comella P., Natale D., Farris A., Gambardella A., Maiorino L., Massidda B., et al. Capecitabine plus oxaliplatin for the first-line treatment of elderly patients with metastatic colorectal carcinoma: final results of the Southern Italy Cooperative Oncology Group Trial 0108. Cancer 104 2 (2005) 282-289 [Jul 15]
21. Feliu J., Salud A., Escudero P., Lopez-Gomez L., Bolanos M., Galan A., et al. XELOX (capecitabine plus oxaliplatin) as first-line treatment for elderly patients over 70 years of age with advanced colorectal cancer. British Journal of Cancer 94 7 (2006) 969-975 [Apr 10]
22. Hurwitz H., Fehrenbacher L., Novotny W., Cartwright T., Hainsworth J., Heim W., et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. New England Journal of Medicine 350 23 (2004) 2335-2342 [Jun 3]
23. H. S. Hochster, L. L. Hart, R. K. Ramanathan, J. D. Hainsworth, E. E. Hedrick, B. H. Childs. Safety and efficacy of oxaliplatin/fluoropyrimidine regimens with or without bevacizumab as first-line treatment of metastatic colorectal cancer (mCRC): Final analysis of the TREE-Study. Journal of Clinical Oncology, 2006 ASCO Annual Meeting Proceedings Part I. Vol 24, No. 18S (June 20 Supplement), 2006: 3510.
24. Cunningham D., Humblet Y., Siena S., Khayat D., Bleiberg H., Santoro A., et al. Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. New England Journal of Medicine 351 4 (2004) 337-345 [Jul 22]
25. Hebbar M., Wacrenier A., Desauw C., Romano O., Cattan S., Triboulet J.P., et al. Lack of usefulness of epidermal growth factor receptor expression determination for cetuximab therapy in patients with colorectal cancer. Anticancer Drugs 17 7 (2006) 855-857 [Aug]
26. Meyerhardt J.A., Zhu A.X., Enzinger P.C., Ryan D.P., Clark J.W., Kulke M.H., et al. Phase II study of capecitabine, oxaliplatin, and erlotinib in previously treated patients with metastastic colorectal cancer. Journal of Clinical Oncology 24 12 (2006) 1892-1897 [Apr 20]
27. Saltz L., Lenz H., and Hochster H. Randomised phase II trial of cetuximab/bevacizumab/irinotecan (CBI) versus cetuximab/irinotecan in irinotecan refractory colorectal cancer. Proceedings of the American Society of Clinical Oncology 23 (2005) (Abstr 3508)